Cullinan Therapeutics Inc. (NASDAQ: CGEM), a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer, reported its fourth-quarter 2025 financial results. The company reported a loss of $7.73 per share on its preferred stock for the quarter.
The company is advancing multiple clinical programs, including zipalertinib, a small molecule in Phase 3 trials for non-small cell lung cancer, CLN-978, a T cell engager for systemic lupus erythematosus and rheumatoid arthritis, and CLN-619, a monoclonal antibody in Phase 1 trials for solid tumors and multiple myeloma.
A detailed analysis of Cullinan Therapeutics Inc’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.